Literature DB >> 10593904

C-terminal residues 621-635 of protein S are essential for binding to factor Va.

M J Heeb1, Y Kojima, J Rosing, G Tans, J H Griffin.   

Abstract

Protein S is anticoagulant in the absence of activated protein C because of direct interactions with coagulation Factors Xa and Va. Synthetic peptides corresponding to amino acid sequences of protein S were tested for their ability to inhibit prothrombinase activity. The peptide containing the C-terminal sequence of protein S, residues 621-635 (PSP14), reversibly inhibited prothrombinase activity in the presence but not in the absence of Factor Va (K(i) approximately 2 microM). PSP14 inhibition of prothrombinase was independent of phospholipids but could be competitively overcome by increasing Factor Xa concentrations, suggesting that the C-terminal region of protein S may compete for a Factor Xa binding site on Factor Va. Studies using peptides with amino acid substitutions suggested that lysines 630, 631, and 633 were critical residues. PSP14 inhibited Factor Va activity in Factor Xa-one-stage clotting assays. PSP14 inhibited protein S binding to immobilized Factor Va. When preincubated with protein S, antibodies raised against PSP14 inhibited binding of protein S to Factor Va and blocked inhibition of prothrombinase activity by protein S. These results show that the C-terminal region of protein S containing residues 621-635 is essential for binding of protein S to Factor Va and that this interaction contributes to anticoagulant action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593904     DOI: 10.1074/jbc.274.51.36187

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Chemical synthesis and spontaneous folding of a multidomain protein: anticoagulant microprotein S.

Authors:  T M Hackeng; J A Fernández; P E Dawson; S B Kent; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Phosphorylation of protein S by platelet kinases enhances its activated protein C cofactor activity.

Authors:  Fabian Stavenuiter; Andrew J Gale; Mary J Heeb
Journal:  FASEB J       Date:  2013-04-11       Impact factor: 5.191

Review 3.  Protein C anticoagulant and cytoprotective pathways.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

4.  Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S.

Authors:  T M Hackeng; S Yegneswaran; A E Johnson; J H Griffin
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

5.  Down-regulation of the clotting cascade by the protein C pathway.

Authors:  Fabian Stavenuiter; Eveline A M Bouwens; Laurent O Mosnier
Journal:  Hematol Educ       Date:  2013

6.  Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.

Authors:  Mary J Heeb; Rolf M Mesters; José A Fernández; Tilman M Hackeng; Ryon K Nakasone; John H Griffin
Journal:  Thromb Haemost       Date:  2013-05-23       Impact factor: 5.249

7.  Role of the PROS1 gene in thrombosis: lessons and controversies.

Authors:  Mary J Heeb
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

8.  Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor.

Authors:  Mary J Heeb; Duane Prashun; John H Griffin; Bonno N Bouma
Journal:  FASEB J       Date:  2009-02-24       Impact factor: 5.191

9.  Understanding the functional difference between growth arrest-specific protein 6 and protein S: an evolutionary approach.

Authors:  Romain A Studer; Fred R Opperdoes; Gerry A F Nicolaes; André B Mulder; René Mulder
Journal:  Open Biol       Date:  2014-10       Impact factor: 6.411

10.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.